XML 199 R197.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Events - Acquisition of ownership interest in Shanghai RAAS (Details)
€ in Thousands
1 Months Ended 12 Months Ended
Mar. 30, 2020
EUR (€)
person
Dec. 31, 2019
EUR (€)
shares
Mar. 31, 2019
Dec. 31, 2019
EUR (€)
shares
Dec. 31, 2018
EUR (€)
Dec. 31, 2017
EUR (€)
Disclosure of non-adjusting events after reporting period [line items]            
Number of subsidiary's shares delivered in exchange for investment | shares       90    
Number of shares received in exchange for investment | shares   1,766,000,000   1,766,000,000    
Investments accounted for using equity method | €   € 114,473   € 114,473 € 226,905 € 219,009
Grifols Diagnostics Solutions, Inc.            
Disclosure of non-adjusting events after reporting period [line items]            
Economic rights (as a percent)     55.00%      
Voting rights (as percent)     60.00%      
Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc.            
Disclosure of non-adjusting events after reporting period [line items]            
Minority shareholders interest       45.00%    
Shanghai RAAS Blood Products, Co. Ltd.            
Disclosure of non-adjusting events after reporting period [line items]            
Proportion of ownership interest in associate     26.20%      
Number of shares received in exchange for investment | shares   1,766,000,000   1,766,000,000    
Gain recognized, fair value adjustment | €   € 57,000        
Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc.            
Disclosure of non-adjusting events after reporting period [line items]            
Number of subsidiary's shares delivered in exchange for investment | shares       90    
Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc.            
Disclosure of non-adjusting events after reporting period [line items]            
Economic rights (as a percent)     45.00%      
Voting rights (in percent)     40.00%      
Acquisition of ownership interest | Grifols Diagnostics Solutions, Inc.            
Disclosure of non-adjusting events after reporting period [line items]            
Economic rights (as a percent) 55.00%          
Voting rights (as percent) 60.00%          
Acquisition of ownership interest | Grifols Diagnostics Solutions, Inc.            
Disclosure of non-adjusting events after reporting period [line items]            
Total number of board members | person 5          
Acquisition of ownership interest | Shanghai RAAS Blood Products, Co. Ltd.            
Disclosure of non-adjusting events after reporting period [line items]            
Total number of board members | person 9          
Acquisition of ownership interest | Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc.            
Disclosure of non-adjusting events after reporting period [line items]            
Number of members that serve of the board of an associate | person 2          
Acquisition of ownership interest | Shanghai RAAS Blood Products, Co. Ltd.            
Disclosure of non-adjusting events after reporting period [line items]            
Proportion of ownership interest in associate 26.20%          
Number of members that serve of the board of an associate | person 3          
Investments accounted for using equity method | € € 1,773,000          
Acquisition of ownership interest | Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc.            
Disclosure of non-adjusting events after reporting period [line items]            
Economic rights (as a percent) 45.00%          
Voting rights contributed (as a percent) 40.00%          
Acquisition of ownership interest | Shanghai RAAS Blood Products, Co. Ltd. | Creat Group Co. Ltd.            
Disclosure of non-adjusting events after reporting period [line items]            
Proportion of ownership interest in associate 26.18%          
Acquisition of ownership interest | Shanghai RAAS Blood Products, Co. Ltd. | RAAS China Limited            
Disclosure of non-adjusting events after reporting period [line items]            
Proportion of ownership interest in associate 22.78%